Ubs Oconnor LLC Crinetics Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 24,693 shares of CRNX stock, worth $1.32 Million. This represents 0.09% of its overall portfolio holdings.

Number of Shares

24,693

Holding current value

$1.32 Million

% of portfolio

0.09%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $18,759 - $23,531	-428 Reduced 1.7%	24,693 $1.26 Million
Q2 2024 Aug 14, 2024	BUY	$42.12 - $51.91 $804,492 - $991,480	19,100 Added 317.22%	25,121 $1.13 Million
Q1 2024 May 15, 2024	SELL	$34.76 - $46.81 $139,630 - $188,035	-4,017 Reduced 40.02%	6,021 $281,000
Q4 2023 Feb 14, 2024	SELL	$25.62 - $37.07 $412,866 - $597,383	-16,115 Reduced 61.62%	10,038 $357,000
Q3 2023 Nov 14, 2023	SELL	$15.97 - $30.59 $479,100 - $917,700	-30,000 Reduced 53.43%	26,153 $777,000
Q2 2023 Aug 14, 2023	BUY	$15.73 - $23.6 $883,286 - $1.33 Million	56,153 New	56,153 $1.01 Billion
Q1 2023 May 15, 2023	SELL	$15.31 - $21.1 $1.21 Million - $1.67 Million	-79,000 Reduced 70.27%	33,421 $536,000
Q4 2022 Feb 14, 2023	BUY	$15.49 - $19.05 $340,175 - $418,357	21,961 Added 24.28%	112,421 $0
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $54,330 - $67,110	3,000 Added 3.43%	90,460 $1.78 Billion
Q2 2022 Aug 12, 2022	BUY	$16.49 - $27.64 $370,365 - $620,794	22,460 Added 34.55%	87,460 $1.63 Million
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $1.11 Million - $1.84 Million	65,000 New	65,000 $1.43 Million

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.88B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account